September 21st 2023
Liposomal tacrolimus led to improvements in hematuria, bleeding sites on cystoscopy, microscopic urine analysis for red blood cells, and urinary symptoms.
September 8th 2023
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
March 8-9, 2024
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Study: Patients taking aspirin can safely undergo PCNL
December 1st 2016Percutaneous nephrolithotomy in the presence of aspirin appears both effective and safe. In a retrospective review of almost 300 PCNL cases, postoperative hemorrhage was uncommon in patients who continued aspirin preoperatively, said Brandon Otto, MD, at the AUA annual meeting in San Diego.
FDA’s updated fluoroquinolone warnings: What urologists should know
November 11th 2016. Prescribers should know that the FDA has updated its warnings to say that fluoroquinolones should not be prescribed to patients who have other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections
Uro Pipeline: FDA committee votes in favor of nocturia treatment approval
November 1st 2016Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Study: Surgery for UUI outperforms medication
October 25th 2016Bilateral replacement of the uterosacral ligaments with a polyvinylidene fluoride (PVDF) mesh (DynaMesh, FEG Textiltechnik mbH) is more effective than medical treatment with solifenacin (Vesicare) for achieving continence in women with urgency urinary incontinence (UUI) associated with only minor pelvic organ prolapse, according to the interim results of a prospective, randomized, crossover clinical trial.
Hydroxycitrate may have utility in treating stones
October 1st 2016A new laboratory study suggests that a widely available nutritional supplement has potential to become a new treatment for the wide majority of kidney stones. Clinical research is still pending, however, and there are important caveats about the findings.
Female SUI system shows durable efficacy, safety
October 1st 2016After meeting its primary endpoint at 3 months in a prospective, randomized, sham-controlled clinical trial, an intravesical pressure-attenuation balloon (Vesair Bladder Control System, Solace Therapeutics) for treatment of female stress urinary incontinence demonstrated durable efficacy and safety after 12 months of follow-up.
Study questions use of pre-op cultures to prevent prosthetic infection
September 28th 2016In this video, Dr. Nicholas Kavoussi sits down with Dr. Arthur L. Burnett, II, of the Urology Times Editorial Council to discuss his 2016 AUA presentation, "Preoperative urine cultures for prosthetic urological surgery: What is the evidence?"
Convective water vapor ablation successful at 2 years
September 1st 2016A treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
Basic Science Research: Trimodal therapy shows promise in oligometastatic PCa
July 1st 2016Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.